BECONASE AQ
LOE ApproachingNDANASALSPRAY, METERED
Approved
Jul 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
BECONASE AQ by GSK is clinical pharmacology mechanism of action following topical administration, beclomethasone dipropionate produces anti-inflammatory and vasoconstrictor effects. Approved for recurrence of nasal polyps following surgical removal. First approved in 1987.
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BECONASE AQ is an intranasal metered spray formulation of beclomethasone dipropionate, a topical corticosteroid indicated for recurrence of nasal polyps following surgical removal. It works by producing anti-inflammatory and vasoconstrictor effects through hydrolysis to its active metabolite beclomethasone-17-monopropionate (B-17-MP), which suppresses multiple inflammatory cell types and mediators.
$0.001BPart D
LOE ApproachingProduct approaching end-of-life with minimal current revenue ($1M spending, 3,065 claims in 2023); limited team growth expected.
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action Following topical administration, beclomethasone dipropionate produces anti-inflammatory and vasoconstrictor effects. The mechanisms responsible for the anti-inflammatory action of beclomethasone dipropionate are unknown. Corticosteroids have been shown to…
Worked on BECONASE AQ at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.